wrong again. Viropro is pleased to announce it has signed a binding Letter of Agreement (“LOA”) with Spectrum Pharmaceuticals, Inc. of Irvine, CA, for the development and clinical production of a biosimilar version of Rituximab, a monoclonal antibody currently used in the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. As part of this LOA, Spectrum will also license the rights to certain technology that will be used in the development of the Rituximab biosimilar.
Viropro holds patents to the technology for the biosimilar version. If it was just as easy as you make it sound SPPI wouldn't need to sign a LOA with VPRO.
Nice try....
Market Data 
Markets 
AI
